Photo generated from www.annalsofoncology.org
Jun 10, 2024, 11:27
Arndt Vogel on a paper by D.E.W. van der Kruijssen et al.
Arndt Vogel shared a post on X:
“Upfront resection vs no resection of the primary tumor in metastatic colorectal cancer:
- Phase 3 CAIRO4, 206 patients
- mOS 18.3 vs 20.1 months
- AEs ≥3° 72% vs 65%
- Upfront PTR to palliative systemic therapy does not improve survival.”
Read further.
Source: Arndt Vogel/X
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 06:49
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12